CSL enters licensing agreement with Arcturus Therapeutics for self-amplifying mRNA technology
Via its vaccine subsidiary CSL Seqirus, CSL will use Arcturus’ tech to support the research, development, manufacture and commercialization of vaccines for COVID-19, influenza, pandemic… Read More »CSL enters licensing agreement with Arcturus Therapeutics for self-amplifying mRNA technology